A260660 Stock Overview
Engages in the researches and develops, produces, and sells medicines in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Korea Arlico Pharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,415.00 |
| 52 Week High | ₩6,090.00 |
| 52 Week Low | ₩3,070.00 |
| Beta | 0.75 |
| 1 Month Change | -0.15% |
| 3 Month Change | -16.61% |
| 1 Year Change | -40.92% |
| 3 Year Change | -58.90% |
| 5 Year Change | -61.58% |
| Change since IPO | -77.11% |
Recent News & Updates
Korea Arlico PharmLtd (KOSDAQ:260660) Is Carrying A Fair Bit Of Debt
Nov 12
There's Reason For Concern Over Korea Arlico Pharm Co.,Ltd.'s (KOSDAQ:260660) Price
Aug 04Recent updates
Korea Arlico PharmLtd (KOSDAQ:260660) Is Carrying A Fair Bit Of Debt
Nov 12There's Reason For Concern Over Korea Arlico Pharm Co.,Ltd.'s (KOSDAQ:260660) Price
Aug 04Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24Should You Be Adding Korea Arlico PharmLtd (KOSDAQ:260660) To Your Watchlist Today?
Mar 02Korea Arlico PharmLtd's (KOSDAQ:260660) Shareholders Are Down 50% On Their Shares
Feb 12
What Is The Ownership Structure Like For Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)?
Jan 25Should You Use Korea Arlico PharmLtd's (KOSDAQ:260660) Statutory Earnings To Analyse It?
Jan 04Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Korea Arlico Pharm Co.,Ltd.'s KOSDAQ:260660) Stock?
Nov 25Shareholder Returns
| A260660 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.9% | 1.4% | -0.8% |
| 1Y | -40.9% | -0.07% | -10.1% |
Return vs Industry: A260660 underperformed the KR Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: A260660 underperformed the KR Market which returned -10.9% over the past year.
Price Volatility
| A260660 volatility | |
|---|---|
| A260660 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A260660 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A260660's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Hang-Gu Lee | www.arlico.co.kr |
Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients.
Korea Arlico Pharm Co.,Ltd. Fundamentals Summary
| A260660 fundamental statistics | |
|---|---|
| Market cap | ₩52.34b |
| Earnings (TTM) | -₩7.52b |
| Revenue (TTM) | ₩182.56b |
0.3x
P/S Ratio-7.0x
P/E RatioIs A260660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A260660 income statement (TTM) | |
|---|---|
| Revenue | ₩182.56b |
| Cost of Revenue | ₩85.31b |
| Gross Profit | ₩97.25b |
| Other Expenses | ₩104.77b |
| Earnings | -₩7.52b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -490.66 |
| Gross Margin | 53.27% |
| Net Profit Margin | -4.12% |
| Debt/Equity Ratio | 54.3% |
How did A260660 perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yieldn/a
Payout RatioDoes A260660 pay a reliable dividends?
See A260660 dividend history and benchmarks| Korea Arlico PharmLtd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 14 2025 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 101 days |
Does A260660 pay a reliable dividends?
See A260660 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 05:28 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Korea Arlico Pharm Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |